Once-Daily Fluticasone Propionate is as Effective as Twice-Daily Treatment in Stable, Mild-to-Moderate Childhood Asthma
Authors: Ian G.C. Hodges1; Thelma A. Netherway2
Source: Clinical Drug Investigation, Volume 25, Number 1, 2005 , pp. 13-22(10)
Publisher: Adis International
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma.Design: Multicentre, randomised, double-blind, parallel-group study.Setting: General practice, 86 UK centres.Patients: 328 children with a diagnosis of asthma and a mean age of 10 years (range 416 years), mean duration of asthma of 5.5 years, and a mean percentage predicted forced expiratory volume in 1 second prior to randomisation of 93% were randomised.Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50
g twice daily via a Diskus inhalation device. Patients whose asthma was well controlled according to predefined criteria were randomised to receive either fluticasone propionate 100
g at night and placebo in the morning (once daily [od] group; n = 151) or fluticasone propionate 50
g twice daily (bd) [bd group; n = 177] for 8 weeks.Main outcome measures: Mean morning peak expiratory flow over the 8 weeks of treatment, recorded daily, adjusted for baseline, age, height and sex.Results: The 90% CI for the treatment difference in morning peak flow (bdod) in the intention-to-treat population was 1.9 to 5.3 L/min, demonstrating clinical equivalence between bd and od administration. Fifteen patients withdrew from the study due to asthma-related problems, ten patients from the od group and five from the bd groups (p = 0.10). Both groups remained well controlled in terms of lung function, symptoms and use of relief medication throughout the study.Conclusions: Once-daily treatment with fluticasone propionate 100
g at night is as effective as 50
g twice daily in children with well controlled mild-to-moderate asthma.
Document Type: Research article
Affiliations: 1: 1 Consultant Paediatrician, Royal Glamorgan Hospital, Llantrisant, Mid Glamorgan, Wales 2: 2 Glaxo SmithKline UK Ltd, Uxbridge, UK
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content

Click here for Page Help